Subsequent Event	3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	13. Subsequent Event On April 14, 2022, we acquired all of the equity interests of vitaCare Prescription Services, Inc. (“vitaCare”), a wholly-owned subsidiary of TherapeuticsMD, Inc., for $150.0 million in cash paid at closing and contingent consideration of up to $7.0 million payable in cash based upon its achievement of certain specified revenue results through 2023. We also established a management incentive plan under which certain continuing vitaCare employees would be eligible to receive up to $10.0 million of additional compensation upon achievement of certain performance milestones. vitaCare is a prescription technology and service platform that simplifies the prescription fulfillment process for consumers taking brand medications by helping them gain access to therapies and stay on those therapies for as long as medically appropriate. The purpose of the acquisition is to strengthen and expand services currently available under our existing pharma manufacturer solutions platform. The acquisition will be accounted for as a business combination under ASC 805, Business Combinations. The determination of the fair values of the acquired assets and assumed liabilities is incomplete due to the recent date of the acquisition.

Subsequent Event

3 Months Ended

Mar. 31, 2022

13. Subsequent Event

On April 14, 2022, we acquired all of the equity interests of vitaCare Prescription Services, Inc. (“vitaCare”), a wholly-owned subsidiary of TherapeuticsMD, Inc., for $150.0 million in cash paid at closing and contingent consideration of up to $7.0 million payable in cash based upon its achievement of certain specified revenue results through 2023. We also established a management incentive plan under which certain continuing vitaCare employees would be eligible to receive up to $10.0 million of additional compensation upon achievement of certain performance milestones. vitaCare is a prescription technology and service platform that simplifies the prescription fulfillment process for consumers taking brand medications by helping them gain access to therapies and stay on those therapies for as long as medically appropriate. The purpose of the acquisition is to strengthen and expand services currently available under our existing pharma manufacturer solutions platform.

The acquisition will be accounted for as a business combination under ASC 805, Business Combinations. The determination of the fair values of the acquired assets and assumed liabilities is incomplete due to the recent date of the acquisition.